During the past 3 years, the average EBITDA Per Share Growth Rate was 36.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 38.50% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 1.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Corbus Pharmaceuticals Holdings was 41.60% per year. The lowest was -181.90% per year. And the median was -34.00% per year.
Competitive Comparison of Corbus Pharmaceuticals Holdings's 5-Year EBITDA Growth Rate
For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corbus Pharmaceuticals Holdings's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Corbus Pharmaceuticals Holdings's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Corbus Pharmaceuticals Holdings 5-Year EBITDA Growth Rate Related Terms
Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Corbus Pharmaceuticals Holdings Business Description
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRBP has been successfully added to your